Source 1primary paper2025MED
Toolkit/dominant-negative TGFβRII CAR-T design
dominant-negative TGFβRII CAR-T design
Also known as: dominant-negative receptor TGFβRII
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Key advances discussed include the use of dominant-negative receptors (e.g., TGFβRII) to combat immunosuppression
Usefulness & Problems
Why this is useful
This engineered CAR-T design uses a dominant-negative receptor example, TGFβRII, to resist suppressive signaling.; countering immunosuppression in solid-tumor CAR-T therapy
Source:
This engineered CAR-T design uses a dominant-negative receptor example, TGFβRII, to resist suppressive signaling.
Source:
countering immunosuppression in solid-tumor CAR-T therapy
Problem solved
The abstract explicitly says this strategy is used to combat immunosuppression.; combat immunosuppression
Source:
The abstract explicitly says this strategy is used to combat immunosuppression.
Source:
combat immunosuppression
Problem links
combat immunosuppression
LiteratureThe abstract explicitly says this strategy is used to combat immunosuppression.
Source:
The abstract explicitly says this strategy is used to combat immunosuppression.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
dominant-negative receptor interferencesuppression resistance to tgfβ-mediated immunosuppressive signalingTechniques
Computational DesignTarget processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: actuator
It requires CAR-T cells engineered to express the dominant-negative receptor component.; requires engineering CAR-T cells with a dominant-negative receptor such as TGFβRII
their application in solid tumors remains a formidable challenge due to obstacles such as the immunosuppressive tumor microenvironment, tumor heterogeneity, and limited T cell persistence
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
CAR-T therapy in solid tumors faces major barriers including an immunosuppressive tumor microenvironment, tumor heterogeneity, and limited T cell persistence.
their application in solid tumors remains a formidable challenge due to obstacles such as the immunosuppressive tumor microenvironment, tumor heterogeneity, and limited T cell persistence
Co-expression of bispecific T cell engagers in CAR-T cells is used to address antigen escape.
the co-expression of bispecific T cell engagers (BiTEs) to address antigen escape
Dominant-negative receptors such as TGFβRII are used to combat immunosuppression in next-generation CAR-T strategies for solid tumors.
Key advances discussed include the use of dominant-negative receptors (e.g., TGFβRII) to combat immunosuppression
Approval Evidence
1 source2 linked approval claimsfirst-pass slug dominant-negative-tgf-rii-car-t-design
Key advances discussed include the use of dominant-negative receptors (e.g., TGFβRII) to combat immunosuppression
Source:
limitationsupports
CAR-T therapy in solid tumors faces major barriers including an immunosuppressive tumor microenvironment, tumor heterogeneity, and limited T cell persistence.
their application in solid tumors remains a formidable challenge due to obstacles such as the immunosuppressive tumor microenvironment, tumor heterogeneity, and limited T cell persistence
Source:
mechanism strategysupports
Dominant-negative receptors such as TGFβRII are used to combat immunosuppression in next-generation CAR-T strategies for solid tumors.
Key advances discussed include the use of dominant-negative receptors (e.g., TGFβRII) to combat immunosuppression
Source:
Comparisons
Source-stated alternatives
Other strategies named in the abstract include cytokine armoring, logic-gated systems, localized delivery, and BiTE co-expression.
Source:
Other strategies named in the abstract include cytokine armoring, logic-gated systems, localized delivery, and BiTE co-expression.
Source-backed strengths
highlighted as a key advance
Source:
highlighted as a key advance
Compared with cytokine armoring
Other strategies named in the abstract include cytokine armoring, logic-gated systems, localized delivery, and BiTE co-expression.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a key advance.
Source:
Other strategies named in the abstract include cytokine armoring, logic-gated systems, localized delivery, and BiTE co-expression.
Ranked Citations
- 1.